Fispemifene

Shares of Apricus Biosciences Inc (NASDAQ: APRI) plunged more than 50 percent on Monday after the company disclosed "disappointing" Phase 2b data. Apricus Biosciences stated that a proof-of-concept study of fispemifene in men with secondary hypogonadism and sexual dysfunction failed...